Search results
Showing 1396 to 1410 of 1809 results for nice guidelines
This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
Smoking: preventing uptake in children and young people (PH14)
This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
This guideline has been updated and replaced by the NICE guideline on social, emotional and mental wellbeing in primary and secondary education (NG223).
Social and emotional wellbeing in secondary education (PH20)
This guideline has been updated and replaced by NICE guideline on social, emotional and mental wellbeing in primary and secondary education (NG223).
Ticagrelor for the treatment of acute coronary syndromes (TA236)
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.
In February 2023, NICE withdrew this guidance following a review. The original guidance published in 2013 and recommended the use of WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension. However the guidance review in 2022 recommended it be withdrawn because it was determined that: The existing medical technologies guidance was considered along with other interventions in the update of NICE's guideline on atrial fibrillation. See evidence review A and evidence review B providing the best advice to the NHS about its use. As evident in NICE's guideline on atrial fibrillation, the evidence base and experts’ advice, the landscape for opportunistically detecting atrial fibrillation in primary care has changed significantly since the original guidance, with a wider range of devices for detecting atrial fibrillation now available.
TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)
NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)
NICE has developed a medtech innovation briefing (MIB) on the Active-B12 assay for diagnosing vitamin B12 deficiency
Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)
Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.